Cadenza Bio, founded in Oklahoma City, Oklahoma, is a preclinical biotechnology company dedicated to developing novel small-molecule drugs targeting demyelinating and inflammatory diseases. Their core mission is to break the cycle of disease by not only alleviating symptoms but halting progression, promoting repair, and restoring quality of life. Cadenza Bio focuses on creating highly selective Estrogen Receptor-targeted therapies that aim to transform patient outcomes and empower individuals suffering from severe medical conditions.

Notable affiliated individuals and investors include key figures in the biotechnology and pharmaceutical sectors, although specific names are not disclosed. The company has achieved significant milestones in preclinical development, positioning itself as a promising player in the biotech industry. Cadenza Bio's innovative approach has the potential to make a substantial impact on the treatment of chronic diseases, offering hope for improved patient care and long-term health benefits.